DAWN Logo

Day One Biopharmaceuticals, Inc. (DAWN) 

NASDAQ
Market Cap
$1.55B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
520 of 776
Rank in Industry
281 of 433

Largest Insider Buys in Sector

DAWN Stock Price History Chart

DAWN Stock Performance

About Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One …

Insider Activity of Day One Biopharmaceuticals, Inc.

Over the last 12 months, insiders at Day One Biopharmaceuticals, Inc. have bought $0 and sold $5.91M worth of Day One Biopharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Day One Biopharmaceuticals, Inc. have bought $34.92M and sold $23.66M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 111,387 shares for transaction amount of $1.11M was made by AI Day1 LLC (10 percent owner) on 2023‑10‑20.

List of Insider Buy and Sell Transactions, Day One Biopharmaceuticals, Inc.

2024-10-31SaleHEAD OF R&D
500
0.0006%
$16.02$8,010+0.07%
2024-09-10SaleHEAD OF R&D
30,000
0.0339%
$14.22$426,675-1.36%
2024-08-16SaleHEAD OF R&D
2,232
0.0027%
$14.00$31,2460.00%
2024-08-16SaleCOO, CFO AND SECRETARY
2,633
0.0031%
$14.00$36,8600.00%
2024-08-16SaleCHIEF EXECUTIVE OFFICER
10,681
0.0127%
$14.00$149,5240.00%
2024-08-16SaleGENERAL COUNSEL
3,202
0.0038%
$14.00$44,8250.00%
2024-07-16SaleHEAD OF R&D
20,000
0.0273%
$16.01$320,226-11.93%
2024-06-21Saledirector
10,000
0.012%
$13.19$131,877+3.00%
2024-06-10SaleHEAD OF R&D
30,000
0.0347%
$12.62$378,588+12.25%
2024-05-16SaleHEAD OF R&D
2,267
0.0026%
$16.08$36,450-13.17%
2024-05-16SaleCHIEF EXECUTIVE OFFICER
7,873
0.009%
$16.08$126,588-13.17%
2024-05-16SaleCOO, CFO AND SECRETARY
2,675
0.0031%
$16.08$43,011-13.17%
2024-05-16SaleGENERAL COUNSEL
3,253
0.0037%
$16.08$52,304-13.17%
2024-05-10SaleHEAD OF R&D
10,000
0.0117%
$16.37$163,743-12.94%
2024-05-03SaleCHIEF EXECUTIVE OFFICER
9,154
0.0109%
$17.85$163,417-18.26%
2024-05-03SaleCOO, CFO AND SECRETARY
8,078
0.0096%
$17.85$144,214-18.26%
2024-05-02SaleCHIEF EXECUTIVE OFFICER
6
<0.0001%
$17.94$108-20.03%
2024-05-02SaleCOO, CFO AND SECRETARY
200
0.0002%
$17.90$3,579-20.03%
2024-05-01SaleCHIEF EXECUTIVE OFFICER
70,051
0.081%
$17.88$1.25M-20.45%
2024-05-01SaleCOO, CFO AND SECRETARY
52,183
0.0604%
$17.89$933,397-20.45%

Insider Historical Profitability

5.29%
AI Day1 LLC10 percent owner
12929322
12.8209%
$15.3480+13.88%
Blavatnik Len
10684638
10.595%
$15.3410+23.65%
Canaan XI L.P.10 percent owner
8464301
8.3933%
$15.3417<0.0001%
Atlas Venture Associates Opportunity I, LLC
766667
0.7602%
$15.3410+23.65%
Gladstone Michael
766667
0.7602%
$15.3410+23.65%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
RA Capital Management, L.P.$129.02M8.947.81M0%+$00.13
Atlas Venture Life Science Advisors Llc$106.23M7.366.43M-15.48%-$19.46M9.86
BlackRock$83.12M5.765.03M-1.85%-$1.56M<0.01
The Vanguard Group$78.87M5.464.77M+0.1%+$78,255.24<0.01
Fidelity Investments$72.76M5.044.4M+10.99%+$7.21M0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.